Mercado mundial de inhibidores de la ciclooxigenasa 1: tendencias de la industria y pronóstico hasta 2031

Análisis y tamaño del mercado de inhibidores de la ciclooxigenasa 1

En 1991, Simmons y sus colegas descubrieron una segunda enzima ciclooxigenasa, denominada ciclooxigenasa-2, derivada de un gen distinto al de la ciclooxigenasa-1. La creciente investigación sobre el uso de inhibidores de la cox 1 y las características tecnológicas avanzadas son las principales responsables del crecimiento del mercado de inhibidores de la ciclooxigenasa 1 a nivel mundial. Además, la creciente incidencia de casos de cáncer y enfermedades neuroinflamatorias también puede aumentar el crecimiento de este mercado.                    

Data Bridge Market Research analiza que el mercado global de inhibidores de la ciclooxigenasa 1, que fue de USD 70.000,12 millones en 2023, se espera que alcance los USD 120.145,42 millones para 2031, y se espera que experimente una CAGR del 7,00% durante el período de pronóstico de 2024 a 2031. "Seco" domina el segmento de tipo de producto del mercado debido a la creciente demanda de inhibidores de la ciclooxigenasa 1. Además de los conocimientos sobre escenarios de mercado como el valor de mercado, la tasa de crecimiento, la segmentación, la cobertura geográfica y los principales actores, los informes de mercado seleccionados por Data Bridge Market Research también incluyen un análisis profundo de expertos, epidemiología de pacientes, análisis de la cartera de proyectos, análisis de precios y marco regulatorio.

Alcance y segmentación del mercado de inhibidores de la ciclooxigenasa 1

Market Definition

Cyclooxygenase 1 inhibitors are a kind of non-steroidal anti-inflammatory drugs. Cyclooxygenase 1 is a type of enzyme that is primarily responsible for pain and inflammation. They are mainly responsible for the production of prostaglandins. The induction of COX2 during inflammation has caused the development of several nonselective therapeutic COX1 and COX2 inhibitors that include ibuprofen, ketoprofen, flurbiprofen, and fenoprofen.

Global Cyclooxygenase 1 Inhibitor Market Dynamics

Drivers

• Increasing Prevalence of Cancer

According to Cancer.org, men tend to have a 1 in 23 lifetime risk of having cancer, on the other hand, women have a 1 in 25. Cancer is the third most common cause of mortality in men and the second most common cancer in women. Around 1.8 million new cases were observed in 2018. Around 39% of cases are diagnosed at an early stage. The 5-year survival rate is nearly 71% if cancer locates to neighboring tissues, organs, or regional lymph nodes. Thus, this factor boosts the market growth.

• Increasing Healthcare Expenditure and Government Support

With the rising prevalence of cancer, the growing awareness for the disease and related treatment is also expanding. Government initiatives tend to offer better and more feasible treatments combined with favorable reimbursement policies which are expected to increase the industry growth. Moreover, increasing acceptance of advanced therapies such as Erbitux, Avastin, and Stivarga is expected to drive the market.

• Expanding Applications in Pain Management

COX-1 inhibitors play a crucial role in pain management, contributing to their prominence in the pharmaceutical market. Their effectiveness in alleviating various types of pain, including post-operative pain and chronic pain conditions, propels their widespread utilization. These inhibitors work by blocking the action of COX-1 enzymes, reducing the production of inflammatory mediators responsible for pain and discomfort. Their role in pain management extends across diverse medical specialties, making them an integral component of pain treatment regimens in orthopedics, neurology, and post-operative care. Their proven efficacy and established safety profile in managing pain position them as indispensable medications in the field of pain management, contributing significantly to their market growth.

Opportunities

• Personalized Medicine and Targeted Therapy

The shift toward personalized medicine and targeted therapies provides an opportunity to leverage COX-1 inhibitors in tailored treatment approaches. Advancements in genetic profiling and biomarker identification enable the identification of patient populations that might benefit most from COX-1 inhibitor therapy. Stratifying patients based on genetic predispositions or specific molecular profiles allows for more precise and targeted treatment strategies. Tailoring COX-1 inhibitor therapies to individual patient characteristics could improve treatment efficacy and minimize adverse effects, aligning with the trend toward personalized healthcare.

• Expanding Therapeutic Applications

Exploring new therapeutic applications for COX-1 inhibitors presents a promising opportunity in the market. While traditionally used for managing inflammation and pain, ongoing research investigates the potential of COX-1 inhibitors in other disease areas. Studies examining their role in cancer prevention, neuroprotection, and cardiovascular diseases offer avenues for expanding their therapeutic scope. Identifying and harnessing these novel applications may open new markets and avenues for COX-1 inhibitors, broadening their utility beyond traditional indications.

Restraints/Challenges

• Adverse Effects and Safety Concerns

Despite their therapeutic benefits, COX-1 inhibitors are associated with certain adverse effects and safety concerns, posing a significant restraint in their market growth. Prolonged use of these inhibitors may lead to gastrointestinal complications such as ulcers, bleeding, and perforation due to their interference with prostaglandin synthesis. The inhibition of COX-1 enzymes, responsible for maintaining gastric mucosal integrity, contributes to these adverse effects.

• Patent Expirations and Generic Competition

The market for COX-1 inhibitors faces challenges due to patent expirations of key medications, leading to the entry of generic versions. The loss of patent exclusivity exposes original drug manufacturers to competition from generic drug manufacturers offering lower-cost alternatives. This scenario significantly impacts the revenue potential of branded COX-1 inhibitors, leading to market erosion and reduced profitability for originators.

This cyclooxygenase 1 inhibitor market report provides details of new recent developments, trade regulations, import-export analysis, production analysis, value chain optimization, market share, impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market. To gain more info on the cyclooxygenase 1 inhibitor market Contact Data Bridge Market Research for an Analyst Brief, our team will help you take an informed market decision to achieve market growth.

Recent Development

• In May 2022, Dr. Reddy's laboratories launched the Ketorolac Tromethamine tablets USP, 10 mg, in the United States market. Ketorolac Tromethamine tablets, 10 mg, is a non-steroidal anti-inflammatory drug indicated for the short-term management of moderately severe acute pain

Global Cyclooxygenase 1 Inhibitor Market Scope

The cyclooxygenase 1 inhibitor market is segmented on the basis of application, types, end-users and distribution channel. The growth amongst these segments will help you analyse meagre growth segments in the industries and provide the users with a valuable market overview and market insights to help them make strategic decisions for identifying core market applications.

Application

• Inflammatory Diseases
• Gastrointestinal Toxicity
• Others

Types

• Selective Cox 1 Inhibitor
• Non-Selective Cox 1 Inhibitor

End User

• Hospitals
• Homecare
• Specialty Clinics
• Others

Distribution Channel

• Hospital Pharmacy
• Online Pharmacy
• Retail Pharmacy

Global Cyclooxygenase 1 Inhibitor Market Regional Analysis/Insights

The cyclooxygenase 1 inhibitor market is analyzed and market size insights and trends are provided by country, application, types, end-users and distribution channel as referenced above.

The countries covered in the market report are U.S., Canada, Mexico, Germany, Italy, U.K., France, Spain, Netherlands, Belgium, Switzerland, Turkey, Russia, rest of Europe, Japan, China, India, South Korea, Australia, Singapore, Malaysia, Thailand, Indonesia, Philippines, rest of Asia-Pacific, Brazil, Argentina, rest of South America, South Africa, Saudi Arabia, U.A.E., Egypt, Israel, and rest of Middle East and Africa.

North America is expected to dominate the market due of the increase in the expenditure for research and development proficiencies, increasing government’s initiatives and improved health care infrastructure in various countries.

Asia-Pacific is expected to exhibit the highest growth rate in the market during the forecast period of 2024 to 2031 due to the increasing government expenditure on healthcare sector and rising technological advancements and initiatives by the government.

La sección de países del informe también proporciona factores de impacto de mercado individuales y cambios en la regulación en el mercado a nivel nacional que afectan las tendencias actuales y futuras del mercado. Puntos de datos como análisis de la cadena de valor aguas abajo y aguas arriba, tendencias técnicas y análisis de las cinco fuerzas de Porter, estudios de casos son algunos de los indicadores utilizados para pronosticar el escenario del mercado para países individuales. Además, la presencia y disponibilidad de marcas globales y sus desafíos enfrentados debido a la competencia grande o escasa de las marcas locales y nacionales, el impacto de los aranceles nacionales y las rutas comerciales se consideran al proporcionar un análisis de pronóstico de los datos del país.   

Crecimiento de la infraestructura de atención de salud Base instalada y penetración de nuevas tecnologías

El mercado de inhibidores de la ciclooxigenasa 1 también le proporciona un análisis detallado del mercado para cada país: el crecimiento del gasto sanitario en equipos de capital, la base instalada de diferentes tipos de productos para el mercado de inhibidores de la ciclooxigenasa 1, el impacto de la tecnología mediante curvas de línea de vida y los cambios en los escenarios regulatorios de la atención médica y su impacto en el mercado de inhibidores de la ciclooxigenasa 1. Los datos están disponibles para el período histórico 2011-2021.

Análisis del panorama competitivo y de la cuota de mercado global de inhibidores de la ciclooxigenasa 1

El panorama competitivo del mercado de inhibidores de la ciclooxigenasa 1 proporciona detalles por competidor. Los detalles incluidos son una descripción general de la empresa, las finanzas de la empresa, los ingresos generados, el potencial de mercado, la inversión en investigación y desarrollo, las nuevas iniciativas de mercado, la presencia global, los sitios e instalaciones de producción, las capacidades de producción, las fortalezas y debilidades de la empresa, el lanzamiento del producto, la amplitud y la variedad del producto, el dominio de la aplicación. Los puntos de datos anteriores proporcionados solo están relacionados con el enfoque de las empresas relacionado con el mercado de inhibidores de la ciclooxigenasa 1.

Algunos de los principales actores que operan en el mercado de inhibidores de la ciclooxigenasa 1 son:

• Jsn Technologies (Reino Unido)
• Boehringer Ingelheim International GmbH (Alemania)
• Bayer AG (Alemania)
• Sabinsa (Estados Unidos)
• Farmacéutica Cadila. (India)
• Mylan NV (Estados Unidos)
• Alembic Pharmaceuticals Limited (India)
• Grupo Zydus (India)
• Aurobindo Pharma (India)
• Cipla Inc. (Estados Unidos)
• Torrent Pharmaceuticals Ltd (India)
• Abbvie, Inc. (Estados Unidos)
• Novartis AG (Suiza)
• Industrias farmacéuticas Teva Ltd (Israel)
• Pfizer Inc (Estados Unidos)
• Hikma Pharmaceuticals PLC (Reino Unido)

SKU-52884